Recent News

• 03.26.2025 - Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
• 03.20.2025 - Optinose Q4 2024 Earnings Call
• 03.20.2025 - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
• 03.20.2025 - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Recent Filings

• 03.26.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.26.2025 - 8-K Current report
• 03.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 8-K Current report
• 03.20.2025 - 8-K Current report
• 03.20.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.20.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material